Reproductive health

Schmidt Futures and the Rhodes Trust Open New Cycle of Rise Applications for Brilliant Teens With 'Rise To' Campaign Featuring Bishop Briggs' Newest Single

Retrieved on: 
Friday, October 21, 2022
Reproductive health, Movement, Medicine, Technology, Government, Life, Rhodes House, Burj Khalifa, Science, Education, Climate, Schmidt Family Foundation, American Leadership Academy, Research, Program, Multimedia, Microsoft Partner Network, Rhodes Scholarship, Communal violence, Myth, Rise (education program), Ogilvy, Cancer, NBA Africa Game 2018, Student, NEW, Mahapola Higher Education Scholarship Trust Fund, Goal, University, Non-governmental organization, Perseverance, United World Colleges, Learning, Spotify, CEO, Awareness, Social media, Optimism, Eric, Partnership, Social justice, UWC, COVID-19, Commerce, Rhodes, Music, Video game, Toy, Auction, Forestry, Online shopping, Risk management, Public relations, Management, Rise, Brigg

NEW YORK, Oct. 21, 2022 /PRNewswire/ -- Schmidt Futures, in partnership with the Rhodes Trust, today announced that young people ages 15 to 17 (as of July 1st, 2023) can apply for the 2023 Rise Global Challenge with the launch of the 'Rise To' campaign. The flagship program of Schmidt Futures and the anchor of a broader $1 billion philanthropic commitment from Eric and Wendy Schmidt, Rise finds brilliant people who need opportunity and supports them for life as they work to serve others. Rise will build a lifelong community of students, teachers, and institutions across sectors who aim to serve others. The program, which identifies young people between the ages of 15 and 17 from around the world, is designed to encourage a lifetime of service and learning by providing support that could include scholarships, career services, and funding opportunities to help these leaders serve others for decades to come.  

Key Points: 
  • Produced by Ogilvy, the campaign seeks to inspire and foster a global community of 15- to 17-year-olds invested in creating a better future.
  • Rise has partnered with multi-platinum singer-songwriter Bishop Briggs, known for her viral track "River," on a series of beautifully shot films and audio ads featuring 2021 Rise Global Winners .
  • "As a new parent, when I wrote "superhuman," I was inspired by this brilliant up-and-coming generation," said Bishop Briggs.
  • Winners featured in the 'Rise To' campaign include:
    Rushank Goyal (India), who advocates against food adulteration in his community by conducting discussion sessions.

IBSA Group and Granata Bio announces first patient screened in pivotal PROGRESS clinical trial of Progesterone-IBSA

Retrieved on: 
Wednesday, October 19, 2022
Reproductive health, Disease, Centers for Disease Control and Prevention timeline, Woman, Vaginal bleeding, Blastocyst, Luteal phase, Progesterone, Patient, ART, Malignancy, Multimedia, IBSA, Transfer, Rest, Plasma protein binding, III, Marketing, Health, CEO, PROGRESS, Breast, Ageing, Safety, Clinical trial, Infertility, Liver, Center, Pregnancy, Thrombophlebitis, Apoplexy, Prevention, Pharmaceutical industry, Birth control

BOSTON, Oct. 20, 2022 /PRNewswire/ -- IBSA Group and Granata Bio today announced the screening of the first patient in the pivotal phase III PROGRESS (PROGesterone fRozenEuploid blaStocyst tranSfer) clinical trial (Clinical Trials.gov Identifier: NCT04549116).

Key Points: 
  • BOSTON, Oct. 20, 2022 /PRNewswire/ -- IBSA Group and Granata Bio today announced the screening of the first patient in the pivotal phase III PROGRESS (PROGesterone fRozenEuploid blaStocyst tranSfer) clinical trial (Clinical Trials.gov Identifier: NCT04549116).
  • The study is expected to enroll about 680 patients between the ages of 35-42 years old.
  • "The IBSA Group is excited for this key milestone in development of our subcutaneous progesterone in the United States.
  • IBSA Group, headquartered in Lugano, Switzerland, is a leader in reproductive health and has a diversified product portfolio of prescription drugs and biologics.

World Vasectomy Day and DKT International Celebrate 10 Years Inspiring Men to Shoulder Responsibility for Family Planning

Retrieved on: 
Wednesday, October 19, 2022
Health, Consumer, Surgery, Other Health, General Health, Men, Living Stage Theatre Company, Reproductive health, Midwestern United States, Birth, ICFP, Movement, Domestic airport, World Vasectomy Day, Sale, Directory, Population, Conference, Woman, GMT, Family, Man, WVDS, International Conference on Population and Development, Intrauterine device, MOH, History, Planned Parenthood, HIV, Vasectomy, Parenthood, Social marketing, WVD, Male, CEO, DKT, HIV/AIDS, MVA, Travel, Shoulder, DKT International, Birth control

DKT International , one of the worlds largest providers of family planning, HIV/AIDS, and safe abortion products and services, is proud to continue its support of World Vasectomy Day (WVD) .

Key Points: 
  • DKT International , one of the worlds largest providers of family planning, HIV/AIDS, and safe abortion products and services, is proud to continue its support of World Vasectomy Day (WVD) .
  • DKTs offices around the world will also be supporting the occasion with their events focused on the need for men to shoulder some of the responsibility for family planning.
  • WVD will be in Thailand from November 14-17 during the International Conference on Family Planning (ICFP) alongside DKT International.
  • We thank DKT for its continuous support in growing the World Vasectomy Day movement, adds Jonathan Stack, co-founder of WVD.

BioSkryb Genomics and Cooper Surgical Ink Multi-Year Deal to Accelerate Clinical Discovery and Diagnostics in Women’s Reproductive Health

Retrieved on: 
Tuesday, October 18, 2022
Science, Other Science, Research, General Health, Health, Technology, Genetics, Other Technology, Reproductive health, GM, Disease, Amplification, Infertility, Woman, CooperVision, Genomics, NYSE, Patient, The Cooper Companies, ART, Research, Workforce, Partnership, Technology, Cooper, PTA, Health, Neurology, CEO, Biopsy, IVF, Innovation, Genetic testing, Genome, Fertility, PGT, Single-cell analysis, Chromosome, Pregnancy, Antibiotics, Medical imaging

Cooper Genomics will utilize the BioSkryb technology to enhance their preimplantation genetic testing (PGT) capabilities.

Key Points: 
  • Cooper Genomics will utilize the BioSkryb technology to enhance their preimplantation genetic testing (PGT) capabilities.
  • The agreement will also permit Cooper Genomics to market and distribute the BioSkryb technology for the PGT and womens reproductive health market globally.
  • The deal spans multiple years and is exclusive in the PGT and Womens Reproductive Health markets.
  • Headquartered in San Ramon, Calif., Cooper has a workforce of more than 12,000 with products sold in over 100 countries.

Variantyx Secures Additional $20M from Kreos Capital, Following $41.5M Investment Round

Retrieved on: 
Tuesday, October 18, 2022
Oncology, Data Management, Health, Technology, Hospitals, Genetics, Managed Care, Lists of diseases, Reproductive health, Technology, Health care, Growth, KREO, General partnership, Patient, Investment, Precision medicine, Dilution of precision (navigation), CEO, Barcode technology in healthcare, Pharmaceutical industry, Medical imaging

These additional funds follow the Companys recent $41.5M Series C-2 equity financing announced in February 2022.

Key Points: 
  • These additional funds follow the Companys recent $41.5M Series C-2 equity financing announced in February 2022.
  • We are very pleased to partner with Kreos Capital as we seek to revolutionize the precision medicine markets said Haim Neerman, CEO of Variantyx.
  • Variantyx is a technology-driven precision medicine company providing disruptive solutions for the genetic disorders, reproductive health, and precision oncology markets.
  • Kreos Capital is the leading growth debt provider in Europe and Israel, backing high-growth companies through every stage of their life-cycle.

Innovation Fertility, Led by Fertility Care Experts, Announces Launch Ahead of ASRM

Retrieved on: 
Tuesday, October 18, 2022
Fertility clinic, Reproductive health, Genetics, Time, Congress, Population, Science, American Society for Reproductive Medicine, Laboratory, Strategic planning, Reproductive medicine, Society, Patient, Research, Technology, Goal, Energy Future Holdings, CEO, IVF, Innovation, Fertility, Gene, ASRM, Pharmaceutical industry, Management

ANAHEIM, Calif., Oct. 18, 2022 /PRNewswire-PRWeb/ -- Follow the science, transform the care. Innovation Fertility, a network of leading IVF clinics and laboratories, has announced its formal launch ahead of the American Society for Reproductive Medicine (ASRM) Scientific Congress & Expo. in Anaheim, CA, October 22-26, 2022. This is the premier event for reproductive medicine, drawing top experts from around the world.

Key Points: 
  • Innovation Fertility , a network of leading IVF clinics and laboratories, has announced its formal launch ahead of the American Society for Reproductive Medicine (ASRM) Scientific Congress & Expo.
  • Innovation Fertility is led by a dynamic and seasoned team of reproductive health and business professionals with years of experience in building successful fertility practices.
  • "We have been working toward this pivotal moment for some time," says Dwight P. Ryan, CEO of Innovation Fertility.
  • Innovation Fertility provides patients with innovative, cutting-edge fertility treatment options to meet their unique family planning goals.

Illumina to Host Second Annual Virtual ESG Investor Event on Friday, October 28, 2022

Retrieved on: 
Monday, October 17, 2022
People, SAN, LinkedIn, Reproductive health, Interest, Investor relations, Webcast, Agriculture, YouTube, ESG, NASDAQ, Research, Twitter, Instagram, Illumina, Inc., Social, Corporate governance, Environmental, social and corporate governance, Corporate social responsibility, Health, Q&A, Genome, DNA, Double-barrelled name, Nightclub, Facebook, Illumina

SAN DIEGO, Oct. 17, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that it will host its second annual virtual Environment, Social and Corporate Governance (ESG) focused investor event at 9:30 am Pacific Time (12:30 pm Eastern Time), Friday, October 28, 2022.

Key Points: 
  • SAN DIEGO, Oct. 17, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that it will host its second annual virtual Environment, Social and Corporate Governance (ESG) focused investor event at 9:30 am Pacific Time (12:30 pm Eastern Time), Friday, October 28, 2022.
  • The webcast will begin at 9:30 am Pacific Time (12:30 pm Eastern Time) on Friday, October 28, 2022.
  • Interested parties may register and access the event through the Investor Info section of Illumina's website at investor.illumina.com or directly at Illumina Virtual ESG Investor Event .
  • A replay of the webcast will be posted on Illumina'swebsite after the event and will be available for at least 30 days following.

Alison Clarke-DeSouza, MD, FACOG, is being recognized by Continental Who's Who

Retrieved on: 
Monday, October 17, 2022
Physician, Reproductive health, Female, Medicine, Obstetrics, Woman, Gynaecology, American Board of Commissioners for Foreign Missions, Family, Volunteering, Patient, Jackson Memorial Hospital, Private practice, Multimedia, American Board of Obstetrics and Gynecology, University, MD, Menopause, Male, Continental, Coral Springs, Florida, American College, View, FACOG

A board-certified Obstetrician and Gynecologist, Dr. Alison Clarke-DeSouza has been practicing medicine since 1983.

Key Points: 
  • A board-certified Obstetrician and Gynecologist, Dr. Alison Clarke-DeSouza has been practicing medicine since 1983.
  • In November 2021, she stepped back from the Obstetrics portion of her practice and began working solely as a Gynecologist.
  • She serves the reproductive health needs of female patients from adolescence through menopause.
  • Dr. Clarke-DeSouza is recognized as a Fellow of the American College of Obstetrics and Gynecologists and is certified by the American Board of Obstetrics and Gynecology.

Femasys to Participate in 78th Annual American Society for Reproductive Medicine (ASRM) Scientific Congress

Retrieved on: 
Friday, October 14, 2022
Tubing (recreation), LinkedIn, Reproductive health, NASDAQ, GLOBE, Society, Infertility, Reproductive medicine, Twitter, ASRM, Episcopal conference, American Society for Reproductive Medicine, Nightclub, Medical imaging

Members of the management team will be showcasing its technologies, including FemaSeed and FemVue, at its booth #1011.

Key Points: 
  • Members of the management team will be showcasing its technologies, including FemaSeed and FemVue, at its booth #1011.
  • Femasys Inc. is a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health.
  • Its two lead product candidates are FemBloc permanent birth control and FemaSeed localized directional insemination for infertility.
  • The Companys product for fallopian tube assessment by ultrasound, FemVue, and FemCerv, an endocervical tissue sampler are currently being marketed in the United States.

PerkinElmer Donation Helps Significantly Expand Capacity for Sickle Cell Disease Screening in Ghana

Retrieved on: 
Thursday, October 13, 2022
Biotechnology, Pharmaceutical, Health, Medical Devices, LinkedIn, Reproductive health, Caregiver, Noguchi, Disease, Sickle cell disease, Government, Informatics, Diagnosis, SCD, Science, YouTube, ESG, Medical research, Patient, Twitter, Instagram, PerkinElmer, Noguchi Memorial Institute for Medical Research, Automation, University, Decision-making, Company, University of Ghana, Safety, Food, Hydroxycarbamide, Ghana Health Service, Center, Fort Irwin National Training Center, Pharmaceutical industry, Facebook

The PerkinElmer-provided MigeleTM Gel Electrophoresis Systems will support Ghanas need for reliable, fast, and cost-efficient SCD screening.

Key Points: 
  • The PerkinElmer-provided MigeleTM Gel Electrophoresis Systems will support Ghanas need for reliable, fast, and cost-efficient SCD screening.
  • With the governments desire to enact a country-wide screening program, the PerkinElmer solutions flexible and scalable design can meet growing high-capacity requirements as screening coverage and sample volumes increase.
  • We would like to congratulate Ghana Health Services and the Sickle Cell Foundation for the milestones gained so far, in advancing the diagnosis and care of patients with the disease in the country.
  • We hope that this donation will facilitate development of Ghanas SCD screening program and will therefore improve the lives of children in the region.